Compare Commvault Systems Inc (CVLT) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Commvault Systems Inc vs GeneDx Holdings Corp — how do they compare? Commvault Systems Inc trades at $156.34 (market cap $6.25B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Commvault Systems Inc is far larger — about 3.1× GeneDx Holdings Corp's market cap, and Commvault Systems Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Commvault Systems Inc for 17 Days and GeneDx Holdings Corp for 19 Days on average.
| CVLT | WGS | |
|---|---|---|
Market Cap | $6.25B | $2.02B |
Volume | 632,727 | 734,640 |
Sector | Technology | Health |
52-Week High | $176.52 | $167.51 |
52-Week Low | $75.18 | $34.51 |
Typical Hold Time | 17 Days | 19 Days |
Enterprise Value | $6.24B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $155.16, up 3.25% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $1.42 exceeding expectations, though valuation metrics remain elevated with a P/E of 96.73. Recent positive developments include AWS Data Competency achievement and expanded FedRAMP authorization, supporting the company's AI-focused resilience platform.
CVLT presents growth potential through its AI integration and cloud partnerships, but faces risks from high valuation multiples and declining profit margins. With 54.55% analyst buy ratings and a $156.55 consensus target, the stock appears fairly valued near current levels, requiring careful monitoring of execution against growth expectations.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Commvault Systems Inc
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
